Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial

NCT07349875 · tracked via the Priya Life Science China tracker

Sponsor

Nanjing First Hospital, Nanjing Medical University

Phase

Phase 4

Started

2026-01-01

Last updated

2026-01-20

Condition(s) studied

Coronary Artery Disease (CAD)

Investigational drug(s) / intervention(s)

Colchicine combined with Guideline-Directed Medical Therapy →

Colchicine combined with Guideline-Directed Medical Therapy: colchicine combined with guideline-directed medical therapy group

Study summary

This study is a prospective, multicenter, randomized controlled clinical trial designed to evaluate whether an anti-inflammatory medication can help improve heart health in patients with stable coronary artery disease.

1. Research Question \& Hypothesis We aim to determine whether adding low-dose colchicine (0.5 mg once daily) to standard medical treatment can further reduce the risk of major cardiovascular events in patients with chronic coronary syndromes (CCS), especially those with non-flow-limiting coronary plaques detected by coronary CT angiography (CCTA).

We hypothesize that colchicine, by reducing vascular inflammation, may help prevent future heart attacks, strokes, and the need for coronary revascularization.
2. Study Population \& Design Design: A rigorously designed, prospective, multicenter, randomized (1:1), controlled superiority trial.

Population: Adults (\>18 years) diagnosed with CCS, identified by CCTA as having at least one coronary artery with ≥50% narrowing but without significant impact on blood flow (CT-FFR \> 0.80).

Intervention:

Intervention Group: Standard guideline-directed medical therapy (GDMT) + colchicine 0.5 mg once daily Control Group: GDMT alone Sample Size: Approximately 3,826 participants, accounting for a 5% dropout rate.
3. Study Endpoints Primary Endpoint: The occurrence of major adverse cardiovascular or cerebrovascular events (MACCE), including:Cardiovascular death; Ischemic stroke; Non-fatal myocardial infarction; Any coronary revascularization. Assessed for 12 months after the last patient is enrolled.

Secondary Endpoints:Occurrence of MACCE over 36 months. Incidence and time to first occurrence of each event category at 12, 24, and 36 months.

Safety Endpoint: Side effects related to colchicine (e.g., gastrointestinal upset, liver or kidney abnormalities, blood disorders, muscle-related reactions).

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria 1. The subject (or legal guardian) understands the trial requirements and treatment procedure, and signs the written informed consent before undergoing any protocol-specified examinations or procedures; 2. Aged ≥18 years; 3. Clinically diagnosed with chronic coronary syndrome (CCS); 4. CCTA confirms ≥50% stenosis in at least one epicardial coronary artery, and CT fractional flow reserve (CT-FFR) \>0.80. Exclusion Criteria 1. Unable or unwilling to provide informed consent; 2. Unable to complete scheduled follow-up; 3. Underwent PCI within the past 3 months; 4. History of coronary artery bypass grafting (CABG); 5. Diagnosis of acute coronary syndromes (ACS); 6. No coronary plaque or plaque stenosis \<50% (confirmed by CCTA); 7. Lesion-specific CT-FFR ≤0.80 in at least one major epicardial coronary artery; 8. Inflammatory bowel disease (Crohn's disease/ulcerative colitis) or chronic diarrhea; 9. History of gastric ulcer or gastric bleeding; 10. Pregnant/lactating women or women of childbearing age without effective contraception; 11. Neuromuscular disease or non-transient creatine kinase (CK) \>3×upper limit of normal (ULN) (confirmed by ≥2 lab tests); 12. Clinically significant non-transient hematological abnormalities (hemoglobin \<100 g/L, hematocrit \<30%/ \>52%, white blood cell count \<3×10⁹/L, platelet count \<100×10⁹/L; confirmed by ≥2 lab tests); 13. Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m² (CKD-EPI formula); 14. Liver dysfunction (alanine aminotransferase \>3×ULN and/or total bilirubin \>2×ULN); 15. Current/planned immunosuppressive therapy; 16. Long-term colchicine use for other indications; 17. Definite/suspected colchicine allergy; 18. Active malignant tumor (expected survival \<1 year); 19. Use of potent CYP3A4/P-glycoprotein inhibitors (e.g., cyclosporine, antiretrovirals, antifungals, erythromycin, clarithromycin) without alternative drugs.

Primary outcome measure(s)

Major adverse cardiovascular and cerebrovascular events (MACCE) — 12 months after enrollment
Composite of cardiovascular death, ischemic stroke, non-fatal myocardial infarction, and any coronary revascularization (follow-up ends when the last enrolled patient completes 12 months of follow-up).

Trial sites (1)

Facility	City	Region	Status
Nanjing First Hospital	Nanjing	China	Recruiting

More Nanjing First Hospital, Nanjing Medical University trials in China

The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM). Starting soon

Gut Microbiota and Prognostic Outcomes in Intracranial Arterial Stenosis Patients（GROW-ICAS） Recruiting

Efficacy of Bioceramic Materials for Bone Defects Repair Recruiting

Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma Recruiting

Different Treatment Strategies on Prognosis of Acute Ischemic Stroke(AISDTS) Recruiting

Other trials for the same condition

Micro-axial Flow Pump-Supported PCI in Complex Coronary Artery Disease With Ischemic LV Dysfunction Starting soon

Effect of Mobile-Based Home Cardiac Rehabilitation on Coronary Plaque Recruiting

Study on Risk Factors and Prognostic Value of Non-target Lesion Progression in Patients With Coronary Artery Disease Active, not recruiting

Clinical Implications of Three-vessel Ultrasonic Flow Ratio Measurement in Patients With Coronary Artery Disease Recruiting

A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07349875 on ClinicalTrials.gov ↗ ← All trials in China